Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The goal of the study is to determine whether a brief, therapeutic interview can help patients improve their pain and health by addressing psychological issues that are known to drive chronic musculoskeletal pain. This randomized, controlled trial tests the efficacy of a brief, one-session therapeutic interview for patients with chronic musculoskeletal pain and histories of childhood adversity. Adults with chronic musculoskeletal pain will be randomized to either a therapeutic interview condition or a waitlist control condition. The therapeutic interview will be 90-minute session during which participants will be encouraged to disclose stressful experiences, express important emotions, and identify connections between their life stress and their pain, which we hope will increase their psychological attributions for pain and reduce their pain, interpersonal problems, and psychological distress. The study will compare the therapeutic interview condition to a delayed interview condition and will follow patients for 5 weeks to identify changes in response to the interview. Participants in the therapeutic interview condition are expected to show more improvement on pain severity, pain interference, psychological distress, interpersonal function, and psychological attitudes toward pain at follow-up, relative to participants in the delayed interview condition.
Description: Brief Pain Inventory pain severity scale (0 - 10; higher values = greater pain severity)
Measure: Change in pain severity from baseline to 5-week follow-up Time: 5-week follow-upDescription: Brief Pain Inventory pain interference scale (0 - 10; higher values = greater pain interference)
Measure: Change in pain interference from baseline to 5-week follow-up Time: 5-week follow-upDescription: PROMIS anxiety scale (0 to 4; higher values = greater anxiety)
Measure: Change in anxiety from baseline to 5-week follow-up Time: 5-week follow-upDescription: PROMIS depression scale (0 to 4; higher values = greater depression)
Measure: Change in depression from baseline to 5-week follow-up Time: 5-week follow-upDescription: PROMIS anger scale (0 to 4; higher values = greater anger)
Measure: Change in anger from baseline to 5-week follow-up Time: 5-week follow-upDescription: Rathus Assertiveness Schedule short form (- 3 to + 3; higher values = greater assertion)
Measure: Change in assertiveness from baseline to 5-week follow-up Time: 5-week follow-upDescription: Affect Phobia Test (1 to 5; lower values = affect phobia)
Measure: Change in affect phobia from baseline to 5-week follow-up Time: 5-week follow-upDescription: Pain attributions psychological subscale (0 to 4; higher values = greater psychological attribution)
Measure: Change in pain attributions to psychological processes from baseline to 5-week follow-up Time: 5-week follow-upDescription: Pain attributions brain subscale (0 to 4; higher values = greater brain attributions)
Measure: Change in pain attributions to brain processes from baseline to 5-week follow-up Time: 5-week follow-upDescription: Alcohol use item (1 to 7; higher = greater alcohol use)
Measure: Change in alcohol use frequency from baseline to 5-week follow-up Time: 5-week follow-upDescription: Item assessing pain medication use (1 to 5; higher = greater medication use)
Measure: Change in pain medication use from baseline to 5-week follow-up Time: 5-week follow-upAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports